Shots:
- ArkBio has reported positive top-line data from the P-II study conducted across 31 clinical sites in China to evaluate safety, tolerability, and clinical efficacy of AK3280 in IPF pts
- Pts who received AK3280 (100/200/300/400mg BID) demonstrated 209.4 mL increase in forced vital capacity (FVC) and a 6.4% adjusted improvement in %pFVC from baseline and other respiratory and lung function improvements especially in the higher dose receiving pts (400mg) vs PBO for 24wks.Â
- AK3280 showed a good safety and tolerability profile without the gastrointestinal intolerability issues associated with the current SoC treatment for IPF
Ref:Â ArkBio |Â Image: ArkBio| Press Release
Related News:-Â Novo Nordisk Enters a ~$2.2B Deal with Septerna to Develop Oral Small Molecules for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
